Chorioretinal atrophy following voretigene neparvovec despite the presence of fundus autofluorescence.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Lima de Carvalho, Jose Ronaldo
Kim, Angela H
Mahajan, Vinit B
Tsang, Stephen H
Sparrow, Janet R
inherited retinal disease
leber congenital amaurosis
Journal titleMolecular genetics & genomic medicine
Publication Begin pagee2038
MetadataShow full item record
AbstractLeber congenital amaurosis (LCA) type 2, due to disease-causing variants in RPE65, is characterized by severe visual loss in early infancy. Current treatments include voretigene neparvovec-rzyl (VN) for RPE65-associated LCA. Herein, we present the long-term follow-up of a patient treated with VN using quantitative autofluorescence (488 nm excitation).
A 9-year-old girl with a diagnosis of LCA with biallelic variants in RPE65 presented for evaluation. The patient underwent VN treatment at the age of 11. The patient returned to clinic at age of 19 at which time imaging revealed evidence of chorioretinal atrophy. Quantitative autofluorescence performed prior to gene therapy and at 6- and 8-year follow-up revealed a central area of fundus autofluorescence.
This case report demonstrates acquisition of fundus autofluorescence at 6- and 8-year follow-up despite the development of chorioretinal atrophy.
CitationKolesnikova M, Lima de Carvalho JR Jr, Parmann R, Kim AH, Mahajan VB, Tsang SH, Sparrow JR. Chorioretinal atrophy following voretigene neparvovec despite the presence of fundus autofluorescence. Mol Genet Genomic Med. 2022 Nov;10(11):e2038. doi: 10.1002/mgg3.2038. Epub 2022 Oct 12. PMID: 36225124; PMCID: PMC9651599.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as © 2022 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
- Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis.
- Authors: Gange WS, Sisk RA, Besirli CG, Lee TC, Havunjian M, Schwartz H, Borchert M, Sengillo JD, Mendoza C, Berrocal AM, Nagiel A
- Issue date: 2022 Jan
- Classification and Growth Rate of Chorioretinal Atrophy after Voretigene Neparvovec-Rzyl for RPE65-Mediated Retinal Degeneration.
- Authors: Bommakanti N, Young BK, Sisk RA, Berrocal AM, Duncan JL, Bakall B, Mathias MT, Ahmed I, Chorfi S, Comander J, Nagiel A, Besirli CG
- Issue date: 2023 Sep 3
- The first gene therapy for RPE65 biallelic dystrophy with voretigene neparvovec-rzyl in Brazil.
- Authors: Ferraz Sallum JM, Godoy J, Kondo A, Kutner JM, Vasconcelos H, Maia A
- Issue date: 2022 Aug
- Subretinal Injection of Voretigene Neparvovec-rzyl in a Patient With RPE65-Associated Leber's Congenital Amaurosis.
- Authors: Hussain RM, Tran KD, Maguire AM, Berrocal AM
- Issue date: 2019 Oct 1
- Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis.
- Authors: Deng C, Zhao PY, Branham K, Schlegel D, Fahim AT, Jayasundera TK, Khan N, Besirli CG
- Issue date: 2022 May